Form 4 for TCRX TScan Therapeutics, Inc.
Accepted 2021-12-27 00:00:00 ET · period of report 2021-12-23 · accession 0000899243-21-049764 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-27 | 2021-12-23 | TCRX | SOUTHWELL DAVID P | CEO, Dir | M - OptEx | $1.97 | +48.7K | 146.6K | +50% | +$95.9K |
| D | 2021-12-27 | 2021-12-23 | TCRX | SOUTHWELL DAVID P | CEO, Dir | M - OptEx | $0.00 | -48.7K | 21.2K | -70% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2021-12-23 | M | A | 48,670 | $1.97 | 146,569 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-12-23 | M | D | 48,670 | $0.00 | 21,161 | D | $1.97 · — to 2029-02-04 | 48,670 Voting Common Stock | (F1) The shares originally subject to this option vested over 4 years of service following October 9, 2018, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. In addition, all of the shares subject to this option shall vest and become fully exercisable upon a Change of Control (as defined in the option agreement). |